Search
Tarenflurbil
go.drugbank.com/drugs/DB05289InvestigationalIt is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models.
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPTI-801
go.drugbank.com/drugs/DB05300InvestigationalIt is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.
Rusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Oportuzumab monatox
go.drugbank.com/drugs/DB05319Investigationaland a truncated portion of Pseudomonas exotoxin A. … VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
VGV-1
go.drugbank.com/drugs/DB05328ExperimentalVGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme co...